Elevated substance-P-like immunoreactivity levels in spinal dialysates during the formalin test in normal and diabetic rats

Brain Research

Volumn 856, Issue 1-2, 2000, Pages 20-27

  Calcutt, Nigel A ^a   Stiller, Carl Olav ^b   Gustafsson, Henrik ^c   Malmberg, Annika B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Diabetes; Formalin test; Neuropath; Pain; Spinal cord; Substance P

Indexed keywords

FORMALDEHYDE; SUBSTANCE P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HYPERALGESIA; IMMUNOREACTIVITY; MICRODIALYSIS; NERVE FIBER TRANSPORT; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; SPINAL CORD; STREPTOZOCIN DIABETES;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; FORMALDEHYDE; HEAT; HINDLIMB; PAIN; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES; SPINAL CORD; SUBSTANCE P;

EID: 0033973007     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)02345-8     Document Type: Article

References (55)

1. P.J. Birch, S.M. Harrison, A.G. Hayes, H. Rogers, M.B. Tyers, The non-peptide NK1 receptor antagonist, (±)-CP-96,345, produces antinociceptive and anti-oedema effects in the rat, Br. J. Pharmacol. 105 (1992) 508-510.
2. E. Brodin, N. Lindefors, C.J. Dalsgaard, E. Theodorsson-Norheim, S. Rosell, Tachykinin multiplicity in rat central nervous system as studied using antisera raised against substance P and neurokinin A, Regul. Pept. 13 (1986) 253-272.
3. E. Brodin, N. Lindefors, U. Ungerstedt, Potassium evoked in vivo release of substance P in rat caudate nucleus measured using a new technique of brain dialysis and an improved substance P-radioimmunoassay, Acta Physiol. Scand. 515 (1983) 17-20.
4. E. Brodin, B. Linderoth, B. Gazelius, U. Ungerstedt, In vivo release of substance P in cat dorsal horn studied with microdialysis, Neurosci. Lett. 76 (1987) 357-362.
5. E. Brodin, A. Rosen, E. Theodorsson, A. Jonczyk, B.E. Sandberg, K. Brodin, Multiple molecular forms of tachykinins in rat spinal cord: a study comparing different extraction methods, Regul. Pept. 52 (1994) 97-110.
6. Y.Q. Cao, P.W. Mantyh, E.J. Carlson, A.M. Gillespie, C.J. Epstein, A.I. Basbaum, Primary afferent tachykinins are required to experience moderate to intense pain, Nature 392 (1998) 390-394.
7. N.A. Calcutt, P. Chen, X.-Y. Hua, Effects of diabetes on tissue content an evoked release of calcitonin gene-related peptide-like immunoreactivity from rat sensory nerves, Neurosci. Lett. 254 (1998) 129-132.
8. N.A. Calcutt, M.C. Jörge, T.L. Yaksh, S.R. Chaplan, Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine, Pain 68 (1996) 293-299.
9. N.A. Calcutt, L. Li, T.L. Yaksh, A.B. Malmberg, Different effects of two aldose reductase inhibitors on nociception and prostaglandin E, Eur. J. Pharmacol. 285 (1995) 189-197.
10. N.A. Calcutt, A.B. Malmberg, T. Yamamoto, T.L. Yaksh, Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats, Pain 58 (1994) 413-420.
11. N.A. Calcutt, D.R. Tomlinson, G.B. Willars, P. Keen, Axonal transport of substance-P-like immunoreactivity in ganglioside-treated diabetic rats, J. Neurol. Sci. 96 (1990) 283-291.
12. V. Chapman, A.H. Dickenson, The effect of intrathecal administration of RP67580, a potent neurokinin 1 antagonist on nociceptive transmission in the rat spinal cord, Neurosci. Lett. 157 (1993) 149-152.
13. C. Courteix, A. Eschalier, J. Lavarenne, Streptozocin-induced dia-betic rats: behavioural evidence for a model of chronic pain, Pain 53 (1993) 81-88.
14. C. De Felipe, J.F. Herrero, J.A. O'Brien, J.A. Palmer, C.A. Doyle, A.J. Smith, J.M. Laird, C. Belmonte, F. Cervero, S.P. Hunt, Altered nociception, analgesia and aggression in mice lacking the receptor for substance, Nature 392 (1998) 394-397.
15. L.T. Diemel, W.J. Brewster, P. Fernyhough, D.R. Tomlinson, Expression of neuropeptides in experimental diabetes; effects of treatment with nerve growth factor or brain-derived neurotrophic factor, Mol. Brain Res. 21 (1994) 171-175.
16. L.T. Diemel, E.J. Stevens, G.B. Willars, D.R. Tomlinson, Depletion of substance P and calcitonin gene-related peptide in sciatic nerve of rats with experimental diabetes; effects of insulin and aldose reductase inhibition, Neurosci. Lett. 137 (1992) 253-256.
17. A.M. Di Giulio, B. Tenconi, R. La Croix, P. Mantegazza, M.P. Abbracchio, F. Cattabeni, A. Gorio, Denervation and hyperinnervation in the nervous system of diabetic animals: II. Monoaminergic and peptidergic alterations in the diabetic encephalopathy, J. Neurosci. Res. 24 (1989) 362-368.
18. M.L. Donadoni, R. Gavezzotti, F. Borella, A.M. Di Giulio, A. Gorio, Experimental diabetic neuropathy. Inhibition of protein mono-ADP-ribosylation prevents reduction of substance P axonal transport, J. Pharmacol. Exp. Ther. 274 (1995) 570-576.
19. R. Gamse, G. Jancso, Reduced neurogenic inflammation in streptozotocin-diabetic rats due to microvascular changes but not to substance P depletion, Eur. J. Pharmacol. 118 (1985) 175-180.
20. C. Garret, A. Carruette, V. Fardin, S. Moussaoui, J.F. Peyronel, J.C. Blanchard, P.M. Laduron, Pharmacological properties of a potent and selective nonpeptide substance P antagonist, Proc. Natl. Acad. Sei. U. S. A. 88 (1991) 10208-10212.
21. N.E. Garrett, M. Malcango, M. Dewhurst, D.R. Tomlinson, alpha-Lipoic acid corrects neuropeptide deficits in diabetic rats via induction of trophic support, Neurosci. Lett. 222 (1997) 191-194.
22. A.J. Harmar, P. Keen, Synthesis, and central and peripheral axonal transport of substance P in a dorsal root ganglion-nerve preparation in vitro, Brain Res. 231 (1982) 379-385.
23. T. Hokfelt, A. Ljungdahl, L. Terenius, R. Eide, G. Nilsson, Immunohistochemical analysis of peptide pathways possibly related to pain and analgesia: enkephalin and substance P, Proc. Natl. Acad. Sci. U. S. A. 74 (1977) 3081-3085.
24. L.N. Holland, B.D. Goldstein, Changes of substance-P-like immunoreactivity in the dorsal horn are associated with the 'phasic' behavioral response to a formalin stimulus, Brain Res. 537 (1990) 287-292.
25. X.-Y. Hua, N.A. Calcutt, A.B. Malmberg, Neonatal capsaicin treatment abolishes formalin-induced spinal PGE2 release, NeuroReport 8 (1997) 2325-2329.
26. X.-Y. Hua, P. Chen, E. Polgar, I. Nagy, M. Marsala, E. Phillips, L. Wollaston, L. Urban, T.L. Yaksh, M. Webb, Spinal neurokinin NK1 receptor down-regulation and antinociception: effects of spinal NK1 receptor antisense oligonucleotides and NK1 receptor occupancy, J. Neurochem. 70 (1998) 688-698.
27. J.L. Hylden, G.L. Wilcox, Intrathecal substance P elicits a caudally-directed biting and scratching behavior in mice, Brain Res. 217 (1981) 212-215.
28. S. Iyengar, P.A. Hipskind, D.R. Gehlert, D. Schober, K.L. Lobb, J.A. Nixon, D.R. Helton, M.J. Kallman, S. Boucher, R. Couture, LY303870, a centrally active neurokinin-1 antagonist with a long duration of action, J. Pharmacol. Exp. Ther. 280 (1997) 774-785.
29. J. Kamei, M. Ogawa, Y. Kasuya, Development of supersensitivity to substance P in the spinal cord of the streptozotocin-induced diabetic rats, Pharmacol. Biochem. Behav. 35 (1990) 473-475.
30. J. Kamei, Y. Ogawa, Y. Ohhashi, Y. Kasuya, Alterations in the potassium-evoked release of substance P from the spinal cord of streptozotocin-induced diabetic rats in vitro, Gen. Pharmacol. 22 (1991) 1093-1096.
31. R.M. Kantner, M.L. Kirby, B.D. Goldstein, Increase in substance P in the dorsal horn during a chemogenic nociceptive stimulus, Brain Res. 338 (1985) 196-199.
32. Y. Kuraishi, N. Hirota, Y. Sato, N. Hanashima, H. Takagi, M. Satoh, Stimulus specificity of peripherally evoked substance P release from the rabbit dorsal horn in situ, Neurosci. 30 (1989) 241-250.
33. F. Lembeck, P. Holzer, Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation, Arch. Pharmacol. 310 (1979) 175-183.
34. J.G. Leme, L. Hamamura, R.H. Migliorini, M.P. Leite, Influence of diabetes upon the inflammatory response of the rat. A pharmacological analysis, Eur. J. Pharmacol. 23 (1973) 74-81.
35. M. Malcangio, N.E. Garrett, D.R. Tomkinson, Nerve growth factor treatment increases stimulus-evoked release of sensory neuropeptides in the rat spinal cord, Eur. J. Neurosci. 9 (1997) 1101-1104.
36. A.B. Malmberg, T.L. Yaksh, Cyclooxygenase inhibition and the spinal release of prostaglandin E2 and amino acids evoked by paw formalin injection: a microdialysis study in unanesthetized rats, J. Neurosci. 15 (1995) 2768-2776.
37. A.B. Malmberg, T.L. Yaksh, N.A. Calcutt, Anti-nociceptive effects of the GM1 ganglioside derivative AGE 44 on the formalin test in normal and streptozotocin-diabetic rats, Neurosci. Lett. 161 (1993) 45-48.
38. M. Marsala, A.B. Malmberg, T.L. Yaksh, The spinal loop dialysis catheter: characterization of use in the unanesthetized rat, J. Neurosci. Methods 62 (1995) 43-53.
39. R. Mathison, J.S. Davison, Altered vascular permeability responses to substance P in diabetic rats: interactions with a nitric oxide synthesis inhibitor, Eur. J. Pharmacol. 240 (1993) 163-168.
40. A. Merighi, J.M. Polak, D.T. Theodosis, Ultrastructural visualization of glutamate and aspartate immunoreactivities in the rat dorsal horn, with special reference to the co-localization of glutamate, substance P and calcitonin-gene related peptide, Neurosci. 40 (1991) 67-80.
41. T. Ohkubo, M. Shibata, H. Takahashi, R. Inoki, Roles of substance P and somatostatin on transmission of nociceptive information induced by formalin in spinal cord, J. Pharmacol. Exp. Ther. 252 (1990) 1261-1268.
42. S. Otsuka, S. Konishi, Release of substance-P-like immunoreactivity from isolated spinal cord of newborn rat, Nature 264 (1976) 83-84.
43. B.S. Phipps, R. Maciewicz, B.B. Sandrew, C.E. Poletti, W.E. Foote, Edinger-Westphal neurons that project to spinal cord contain substance P, Neurosci. Lett. 36 (1983) 125-131.
44. J.P. Robinson, G.B. Willars, D.R. Tomlinson, P. Keen, Axonal transport and tissue contents of substance P in rats with long-term streptozotocin-diabetes. Effects of the aldose reductase inhibitor 'statil', Brain Res. 426 (1987) 339-348.
45. N.M. Rupniak, E. Carlson, S. Boyce, J.K. Webb, R.G. Hill, Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils, Pain 67 (1996) 189-195.
46. T. Sakurada, K. Katsumata, Y. Manome, K. Tan-No, S. Sakurada, K. Kisara, M. Ohba, Antinociceptive effects in the formalin and capsaicin tests after intrathecal adminuteistration of substance P analogues in mice, Eur. J. Pharmacol. 242 (1993) 47-52.
47. T. Sakurada, K. Katsumata, H. Yogo, K. Tan-No, S. Sakurada, M. Ohba, K. Kisara, The neurokinin-1 receptor antagonist, sendide, exhibits antinociceptive activity in the formalin test, Pain 60 (1995) 175-180.
48. M.W. Salter, J.L. Henry, Responses of functionally identified neurones in the dorsal horn of the cat spinal cord to substance P, neurokinin A and physalaemin, Neurosci. 43 (1991) 601-610.
49. R.J. Traub, The spinal contribution of substance P to the generation and maintenance of inflammatory hyperalgesia in the rat, Pain 67 (1996) 151-161.
50. C. Tsigos, L.T. Diemel, A. White, D.R. Tomlinson, R.J. Young, Cerebrospinal fluid levels of substance P and calcitonin gene-related peptide: correlation with sural nerve levels and neuropathic signs in sensory diabetic polyneuropathy, Clin. Sci. 84 (1993) 305-311.
51. Yaksh, T.M. Jessell, R. Gamse, A.W. Mudge, S.E. Leeman, Intrathecal morphine inhibits substance P release from mammalian spinal cord in vivo, Nature 286 (1980) 155-157.
52. T. Yamamoto, T.L. Yaksh, Stereospecific effects of a nonpeptidic NK1 selective antagonist, CP-96,345: antinociception in the absence of motor dysfunction, Life Sei. 49 (1991) 1955-1963.
53. T. Yamamoto, T.L. Yaksh, Comparison of the antinociceptive effects of pre- and posttreatment with intrathecal morphine and MK801, an NMDA antagonist, on the formalin test in the rat, Anesthesiology 77 (1992) 757-763.
54. K. Yasphal, D.M. Wright, J.L. Henry, Substance P reduces tail-flick latency: implications for chronic pain syndromes, Pain 14 (1982) 155-167.
55. A. Zimmer, A.M. Zimmer, J. Baffi, T. Usdin, K. Reynolds, M. Konig, M. Palkovits, E. Mezey, Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene, Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 2630-2635.